4,5-dimethyl-1H-1,3-benzodiazol-2-amine | 67469-22-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 4,5-dimethyl-1H-1,3-benzodiazol-2-amine
• 英文别名: 2-Amino-4,5-dimethylbenzimidazol；4,5-dimethyl-1(3)H-benzoimidazol-2-ylamine；4,5-dimethyl-2-aminobenzimidazole；4,5-dimethyl-1H-benzimidazol-2-amine
• CAS: 67469-22-1
• 化学式: C₉H₁₁N₃
• 分子量: 161.206
• InChiKey: UGQOAAAVARWPRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  丙烯酸甲酯（MA） 、 4,5-dimethyl-1H-1,3-benzodiazol-2-amine 以 乙醇 为溶剂， 生成 6,7-Dimethyl-3,4-dihydropyrimido<1,2-a>benzimidazol-2(1H)-on
  参考文献：
  名称：

  Pyrimido[1,2-a ]benzimidazole derivatives

  摘要：

  这项发明涉及3,4-二氢嘧啶并[1,2-a]苯并咪唑衍生物，在6、7、8或9位置带有一个或多个取代基；它们的制备和制造过程；以及它们的药物组合物。这些化合物抑制血小板的聚集，可在体内用于治疗或预防血栓形成或闭塞性血管疾病，或在体外用于帮助稳定血小板制剂。该发明的代表性化合物是7-和8-乙酰基-3,4-二氢嘧啶并[1,2-a]苯并咪唑-2(1H)-酮。

  公开号：

  US04167569A1

文献信息

• [EN] NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS UTILES EN TANT QU'INHIBITEURS DE S100
  申请人：ACTIVE BIOTECH AB

  公开号：WO2015177367A1

  公开（公告）日：2015-11-26

  A compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.

  式（I）的化合物或其药用盐以及包含该化合物的药物组合物。该化合物是S100A9与相互作用伙伴（如RAGE、TLR4和EMMPRIN）之间相互作用的抑制剂，因此在治疗癌症、自身免疫性疾病、炎症性疾病和神经退行性疾病等疾病方面是有用的。
• Inhibition and Dispersion of Bacterial Biofilms with 2-Aminobenzimidazole Derivatives
  申请人：BLACKWELL Helen

  公开号：US20130136782A1

  公开（公告）日：2013-05-30

  Compounds described herein inhibit biofilm formation or disperse pre-formed biofilms of Gram-negative bacteria. Biofilm-inhibitory compounds can be encapsulated or contained in a polymer matrix for controlled release. Coatings, films, multilayer films, hydrogels, microspheres and nanospheres as well as pharmaceutical compositions and disinfecting compositions containing biofilm-inhibitory compounds are also provided. Methods for inhibiting formation of biofilms or dispersing already formed biofilms are provided. Methods for treating infections of gram-negative bacteria which form biofilms, particularly those of Pseudomonas and more particularly P. aeruginosa.

  本文描述的化合物可以抑制革兰氏阴性细菌的生物膜形成或分散已形成的生物膜。生物膜抑制化合物可以被封装或包含在聚合物基质中以进行控制释放。此外，还提供了包含生物膜抑制化合物的涂层、薄膜、多层薄膜、水凝胶、微球和纳米球，以及含有生物膜抑制化合物的制药组合物和消毒组合物。提供了抑制生物膜形成或分散已形成生物膜的方法。还提供了治疗革兰氏阴性细菌感染的方法，特别是那些形成生物膜的假单胞菌，尤其是P. aeruginosa。
• [EN] AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION<br/>[FR] AMINOBENZIMIDAZOLES ET BENZIMIDAZOLES UTILISES EN TANT QU'INHIBITEURS DE LA REPLICATION DU VIRUS SYNCYTIAL RESPIRATOIRE
  申请人：TIBOTEC PHARM LTD

  公开号：WO2005058869A1

  公开（公告）日：2005-06-30

  Aminobenzimidazoles and benzimidazoles having inhibitory activity on RSV replication and having the formula (I) the prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms thereof; wherein G is a direct bond or C1-10alkanediyl optionally substituted with one or more hydroxy, C1-6alkyloxy, Ar1Cl-6alkyloxy, C1-6alkylthio, Ar1C1-6alkylthio, HO(-CH2-CH2-O)n-, C1-6alkyloxy(-CH2-M2-O)n- or Ar1Cl-6alkyloxy(-CH2-C2-O)n-; R1 is Ar1 or a monocyclic or bicyclic heterocycle; Q is hydrogen, amino or mono- or di(C1-4alkyl)amino; one of R2a and R3a is selected from halo, optionally mono- or polysubstituted C1-6alkyl, optionally mono- or polysubstituted C2-6alkenyl, nitro, hydroxy, Ar2, N(R4aR4b), N(R4aR4b)sulfonyl, N(R4aR4b)carbonyl, C1-6alkyloxy, Ar2oxy, Ar2C1-6alkyloxy, carboxyl, C1-6alkyloxycarbonyl, or -C(=Z)Ar2; and the other one of R2a and R3a is hydrogen; in case R2a is different from hydrogen then R2b is hydrogen, C1-6alkyl or halogen and R3b is hydrogen; in case R3a is different from hydrogen then R3b is hydrogen, C1-6alkyl or halogen and R2b is hydrogen. Compositions containing these compounds as active ingredient and processes for preparing these compounds and compositions.

  氨基苯并咪唑和对RSV复制具有抑制活性的苯并咪唑，其具有式(I)的前药、N-氧化物、加合盐、季铵盐、金属配合物和立体化学异构体形式；其中G是直接键或C1-10烷二基，可选地取代一个或多个羟基、C1-6烷氧基、Ar1Cl-6烷氧基、C1-6烷基硫氧基、Ar1C1-6烷基硫氧基、HO(-CH2- -O)n-、C1-6烷氧基(- -M2-O)n-或Ar1Cl-6烷氧基(- -C2-O)n-；R1是Ar1或单环或双环杂环；Q是氢、氨基或单或双(C1-4烷基)氨基；R2a和R3a中的一个选择自卤素、可选地单或多取代的C1-6烷基、可选地单或多取代的C2-6烯基、硝基、羟基、Ar2、N(R4aR4b)、N(R4aR4b)磺酰基、N(R4aR4b)羰基、C1-6烷氧基、Ar2氧基、Ar2C1-6烷氧基、羧基、C1-6烷氧羰基或-C(=Z)Ar2；R2a和R3a中的另一个是氢；如果R2a不同于氢，则R2b是氢、C1-6烷基或卤素，而R3b是氢；如果R3a不同于氢，则R3b是氢、C1-6烷基或卤素，而R2b是氢。含有这些化合物作为活性成分的组合物以及制备这些化合物和组合物的方法。
• Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof
  申请人：Brown R. Truman

  公开号：US20060089316A1

  公开（公告）日：2006-04-27

  Disclosed are methods of using various compounds, which are known to bind to 3-deoxyglucosone (3DG) or precursors thereof, in order to reduce a susceptibility to tumor formation and/or to prevent or delay onset of tumor formation induced by 3DG and its precursors. Also disclosed is the reduction of 3DG levels in high fructose corn syrop so that the high fructose corn syrup is less likely to induce tumor formation.

  公开了使用各种已知与3-脱氧葡萄糖酮（3DG）或其前体结合的化合物的方法，以减少对肿瘤形成的易感性和/或预防或延迟由3DG及其前体诱导的肿瘤形成。还公开了降低高果糖玉米糖浆中3DG水平的方法，以使高果糖玉米糖浆不太可能诱导肿瘤形成。
• AMINO-BENZIMIDAZOLES DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION
  申请人：Bonfanti Jean-Francois

  公开号：US20090036466A1

  公开（公告）日：2009-02-05

  The present invention concerns amino-benzimidazoles having inhibitory activity on the replication of the respiratory syncytial virus and having the formula their prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms wherein Q is Ar 1 or C 1-6 alkyl substituted with one or more substituents selected from trifluoromethyl, C 3-7 cycloalkyl, Ar 2 , hydroxy, C 1-4 alkoxy, C 1-4 alkylthio, Ar 2 -oxy-, Ar 2 -thio-, Ar 2 (CH 2 ) n oxy, Ar 2 (CH 2 ) n thio, hydroxycarbonyl, aminocarbonyl, C 1-4 alkylcarbonyl, Ar 2 -carbonyl, C 1-4 alkoxycarbonyl, Ar 2 (CH 2 ) n carbonyl, aminocarbonyloxy, C 1-4 alkylcarbonyloxy, Ar 2 -carbonyloxy, Ar 2 (CH 2 ) n carbonyloxy, hydroxy-C 2-4 -alkyloxy, C 1-4 alkoxycarbonyl(CH 2 ) n oxy, mono- or di(C 1-4 alkyl)-aminocarbonyl, mono- or di(C 1-4 alkyl)aminocarbonyloxy, aminosulfonyl, mono- or di(C 1-4 alkyl)aminosulfonyl, dioxolanyl optionally substituted with one or two C 1-6 alkyl radicals, and a heterocycle selected from pyrrolidinyl, pyrrolyl, dihydropyrrolyl, thiazolidinyl, imidazolyl, triazolyl, piperidinyl, homopiperidinyl, piperazinyl, pyridyl and tetrahydropyridyl, which each may optionally be substituted with oxo or C 1-6 alkyl; G is a direct bond or optionally substituted C 1-10 alkanediyl R 1 is Ar 1 or a monocyclic or bicyclic heterocycle; one of R 2a and R 3a is C 1-6 alkyl and the other one of R 2a and R 3a is hydrogen; in case R 2a is different from hydrogen then R 2b is hydrogen or C 1-6 alkyl, and R 3b is hydrogen; in case R 3a is different from hydrogen then R 3b is hydrogen or C 1-6 alkyl, and R 2b is hydrogen; Ar 1 is phenyl or substituted phenyl and Ar 2 is phenyl or substituted phenyl. It further concerns their preparation and compositions comprising them, as well as their use as a medicine.

  本发明涉及对呼吸道合胞病毒复制具有抑制活性的氨基苯并咪唑，其具有以下结构式： 其中Q是Ar1或C1-6烷基，其被一个或多个从三氟甲基，C3-7环烷基，Ar2，羟基，C1-4烷氧基，C1-4烷基硫基，Ar2-氧基，Ar2-硫基，Ar2(CH2)noxy，Ar2( )nthio，羟基羧酸基，氨基羧酸基，C1-4烷基羧酸基，Ar2-羧酸基，C1-4烷氧羧酸基，Ar2( )ncarbonyl，氨基羧酸酯基，C1-4烷基羧酸酯基，Ar2-羧酸酯基，Ar2( )ncarbonyloxy，羟基-C2-4-烷氧基，C1-4烷氧羧酸基( )noxy，单烷基或双烷基氨基羧酸基，单烷基或双烷基氨基羧酸酯基，氨基磺酰基，单烷基或双烷基氨基磺酰基，二氧杂环己烷基，其可选地被一个或两个C1-6烷基基团取代，以及从吡咯烷基，吡咯基，二氢吡咯基，噻唑烷基，咪唑基，三唑基，哌啶基，同型哌啶基，哌嗪基，吡啶基和四氢吡啶基中选择的杂环，每个杂环都可以选择性地被氧代或C1-6烷基取代; G是直接键或可选地取代的C1-10烷二基; R1是Ar1或单环或双环杂环; R2a和R3a中的一个是C1-6烷基，另一个是氢; 如果R2a与氢不同，则R2b是氢或C1-6烷基，而R3b是氢; 如果R3a与氢不同，则R3b是氢或C1-6烷基，而R2b是氢; Ar1是苯基或取代苯基，而Ar2是苯基或取代苯基。本发明还涉及其制备和包含它们的组合物，以及它们作为药物的用途。